Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
PBLA Panbela Therapeutics
0.097
+0.001+1.04%
Symbol
PBLA
Company Name
Panbela Therapeutics
Listing Date
08/28/2020
Establishment Date
2011
CEO
Dr. Jennifer K Simpson, PhD
Market
NASDAQ
Employees
6
Securities Type
DR
Fiscal Year Ends
12-31
Address
712 Vista Boulevard,Suite 305
City
Waconia
Province
Minnesota
Country
United States of America
Zip code
55387
Phone
1-952-479-1196
Profile
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.
Company Overview
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.
CEO: Dr. Jennifer K Simpson, PhD
Market: NASDAQ
Listing Date: 08/28/2020
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist